| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| R Youn. Update on Parkinson's disease. American family physician. vol 59. issue 8. 1999-05-05. PMID:10221302. |
idiopathic parkinson's disease is caused by the progressive loss of dopaminergic neurons in the substantia nigra and nigrostriatal pathway of the midbrain. |
1999-05-05 |
2023-08-12 |
Not clear |
| B Sadzot, J Sheldon, J Flesher, R F Dannals, A P Schachat, J J Fros. Tracers for imaging melanin with positron emission tomography. Synapse (New York, N.Y.). vol 31. issue 1. 1999-05-04. PMID:10025678. |
these results suggest that with a high resolution pet camera it may be feasible to image the melanin-containing cells (dopaminergic neurons) of the substantia nigra in the central nervous system, which could be of interest for the study of parkinson's disease. |
1999-05-04 |
2023-08-12 |
mouse |
| M A Montoya-Cabrera, P Escalante-Galindo, J C Rivera-Rebolledo, F Higuera-Romero, V Hernandez-Gutiérre. [Acute methyl parathion poisoning with extrapyramidal manifestations not previously reported]. Gaceta medica de Mexico. vol 135. issue 1. 1999-05-03. PMID:10204315. |
although an absolute causal relationship of the transient extrapyramidal symptomatology to the organophosphate exposure cannot be clearly established in this case, we speculate a possible delayed inhibition of the dopaminergic receptors in the substantia nigra and the basal ganglia. |
1999-05-03 |
2023-08-12 |
Not clear |
| M Blu. A null mutation in TGF-alpha leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. Nature neuroscience. vol 1. issue 5. 1999-04-28. PMID:10196526. |
a null mutation in tgf-alpha leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. |
1999-04-28 |
2023-08-12 |
mouse |
| S Harper, J Bilsland, L Young, L Bristow, S Boyce, G Mason, M Rigby, L Hewson, D Smith, R O'Donnell, D O'Connor, R G Hill, D Evans, C Swain, B Williams, F Heft. Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo. Neuroscience. vol 88. issue 1. 1999-04-26. PMID:10051205. |
the ability of gpi-1046 to promote the recovery of dopaminergic function following unilateral 6-hydroxydopamine lesions of the substantia nigra was also tested in rats. |
1999-04-26 |
2023-08-12 |
rat |
| S Harper, J Bilsland, L Young, L Bristow, S Boyce, G Mason, M Rigby, L Hewson, D Smith, R O'Donnell, D O'Connor, R G Hill, D Evans, C Swain, B Williams, F Heft. Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo. Neuroscience. vol 88. issue 1. 1999-04-26. PMID:10051205. |
morphometric analysis failed to reveal any changes in either the density of tyrosine hyroxylase-positive fibres in dopaminergic target areas or in cell numbers in the substantia nigra in both experiments. |
1999-04-26 |
2023-08-12 |
rat |
| A G Riedl, P M Watts, R J Edwards, T Schulz-Utermoehl, A R Boobis, P Jenner, C D Marsde. Expression and localisation of CYP2D enzymes in rat basal ganglia. Brain research. vol 822. issue 1-2. 1999-04-21. PMID:10082895. |
lesioning of the nigro-striatal tract to cause almost a complete loss of tyrosine hydroxylase containing neurones in the substantia nigra, also reduced the number of neurones expressing cyp2d5 by 50%, indicating that cyp2d5 is expressed in dopaminergic neurones. |
1999-04-21 |
2023-08-12 |
rat |
| T L Walters, I Irwin, K Delfani, J W Langston, A M Janso. Diethyldithiocarbamate causes nigral cell loss and dopamine depletion with nontoxic doses of MPTP. Experimental neurology. vol 156. issue 1. 1999-04-21. PMID:10192777. |
the purpose of the present study was twofold: (i) to carefully characterize the effects of ddc on mptp-induced degeneration of dopaminergic neurons in substantia nigra pars compacta using unbiased, stereological cell counting techniques and (ii) to determine whether or not ddc can convert a nontoxic dose of mptp into one which is clearly toxic on dopaminergic neurons in the substantia nigra. |
1999-04-21 |
2023-08-12 |
mouse |
| Y Yue, D A Widmer, A K Halladay, D P Cerretti, G C Wagner, J L Dreyer, R Zho. Specification of distinct dopaminergic neural pathways: roles of the Eph family receptor EphB1 and ligand ephrin-B2. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 19. issue 6. 1999-04-13. PMID:10066262. |
dopaminergic neurons in the substantia nigra and ventral tegmental area project to the caudate putamen and nucleus accumbens/olfactory tubercle, respectively, constituting mesostriatal and mesolimbic pathways. |
1999-04-13 |
2023-08-12 |
mouse |
| Y Yue, D A Widmer, A K Halladay, D P Cerretti, G C Wagner, J L Dreyer, R Zho. Specification of distinct dopaminergic neural pathways: roles of the Eph family receptor EphB1 and ligand ephrin-B2. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 19. issue 6. 1999-04-13. PMID:10066262. |
ephb1 and ephrin-b2 are expressed in complementary patterns in the midbrain dopaminergic neurons and their targets, and the ligand specifically inhibits the growth of neurites and induces the cell loss of substantia nigra, but not ventral tegmental, dopaminergic neurons. |
1999-04-13 |
2023-08-12 |
mouse |
| M J Wilby, S R Sinclair, E M Muir, R Zietlow, K H Adcock, P Horellou, J H Rogers, S B Dunnett, J W Fawcet. A glial cell line-derived neurotrophic factor-secreting clone of the Schwann cell line SCTM41 enhances survival and fiber outgrowth from embryonic nigral neurons grafted to the striatum and to the lesioned substantia nigra. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 19. issue 6. 1999-04-13. PMID:10066280. |
we next looked to see whether bridge grafts of gdnf-secreting sctm41 cells would promote the growth of axons to their striatal targets from dopaminergic neurons implanted orthotopically into the 6-ohda-lesioned substantia nigra. |
1999-04-13 |
2023-08-12 |
rat |
| J M Burgunde. Pathophysiology of akinetic movement disorders: a paradigm for studies in fibromyalgia? Zeitschrift fur Rheumatologie. vol 57 Suppl 2. 1999-04-07. PMID:10025078. |
the reason of this dysfunction in parkinson's disease is a decreased nigral dopaminergic efferent innervation due to a neuronal degeneration in the pars compacta of the substantia nigra. |
1999-04-07 |
2023-08-12 |
Not clear |
| C Grüsser, U Grüsser-Cornehl. Improvement in motor performance of Weaver mutant mice following lesions of the cerebellum. Behavioural brain research. vol 97. issue 1-2. 1999-03-29. PMID:9867243. |
a partial loss of purkinje cells (pc) and a degeneration of dopaminergic cells in the substantia nigra have also been found. |
1999-03-29 |
2023-08-12 |
mouse |
| M Morari, M Marti, S Sbrenna, K Fuxe, C Bianchi, L Bean. Reciprocal dopamine-glutamate modulation of release in the basal ganglia. Neurochemistry international. vol 33. issue 5. 1999-03-18. PMID:9874089. |
this topic has been the object of interest since the late 70's, particularly in the striatum and in midbrain dopaminergic areas (substantia nigra and ventral tegmental area). |
1999-03-18 |
2023-08-12 |
rat |
| G Page, S Chalon, L Barrier, A Piriou, F Hugue. Characterization of both dopamine uptake systems in rat striatal slices by specific pharmacological tools. Neurochemistry international. vol 33. issue 5. 1999-03-18. PMID:9874096. |
a lesion into the substantia nigra of animals by injection of 6-hydroxydopamine, a neurotoxic substance of nigrostriatal dopaminergic neurons led to the suppression of both da uptake systems. |
1999-03-18 |
2023-08-12 |
rat |
| P M Watts, A G Riedl, D C Douek, R J Edwards, A R Boobis, P Jenner, C D Marsde. Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase. Neuroscience. vol 86. issue 2. 1999-03-16. PMID:9881865. |
the expression of cyp2e1 in dopaminergic neurons in substantia nigra raises the possibility of a causal association with parkinson's disease. |
1999-03-16 |
2023-08-12 |
rat |
| D S Fan, M Ogawa, K I Fujimoto, K Ikeguchi, Y Ogasawara, M Urabe, M Nishizawa, I Nakano, M Yoshida, I Nagatsu, H Ichinose, T Nagatsu, G J Kurtzman, K Ozaw. Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Human gene therapy. vol 9. issue 17. 1999-02-26. PMID:9853519. |
parkinson's disease (pd) is characterized by the progressive loss of the dopaminergic neurons in the substantia nigra and a severe decrease in dopamine in the striatum. |
1999-02-26 |
2023-08-12 |
rat |
| J M Tepper, B C Sun, L P Martin, I Crees. Functional roles of dopamine D2 and D3 autoreceptors on nigrostriatal neurons analyzed by antisense knockdown in vivo. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 17. issue 7. 1999-02-25. PMID:9065512. |
two different 19-mer antisense oligodeoxynucleotides complementary to the initial coding regions of dopamine d2 or d3 receptor mrna were infused unilaterally into the substantia nigra of rats for 3-6 d to suppress synthesis of d2 and/or d3 receptors on substantia nigra dopaminergic neurons, thereby producing specific reductions of d2 and/or d3 receptors. |
1999-02-25 |
2023-08-12 |
rat |
| A Inanobe, Y Yoshimoto, Y Horio, K I Morishige, H Hibino, S Matsumoto, Y Tokunaga, T Maeda, Y Hata, Y Takai, Y Kurach. Characterization of G-protein-gated K+ channels composed of Kir3.2 subunits in dopaminergic neurons of the substantia nigra. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 19. issue 3. 1999-02-25. PMID:9920664. |
characterization of g-protein-gated k+ channels composed of kir3.2 subunits in dopaminergic neurons of the substantia nigra. |
1999-02-25 |
2023-08-12 |
Not clear |
| M S Saporito, E M Brown, M S Miller, S Carswel. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. The Journal of pharmacology and experimental therapeutics. vol 288. issue 2. 1999-02-22. PMID:9918541. |
cep-1347/kt-7515 was assessed for neuroprotective activity in a low dose mptp model (20 mg/kg) where there was a 50% loss of striatal dopaminergic terminals in the absence of substantia nigra neuronal loss, and a high dose (40 mg/kg) mptp model where there was a complete loss of dopaminergic terminals and 80% loss of dopaminergic cell bodies. |
1999-02-22 |
2023-08-12 |
mouse |